Insmed Incorporated Company Profile (NASDAQ:INSM)

About Insmed Incorporated

Insmed Incorporated logoInsmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company's lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company's earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSM
  • CUSIP:
Key Metrics:
  • Previous Close: $14.39
  • 50 Day Moving Average: $15.01
  • 200 Day Moving Average: $13.93
  • 52-Week Range: $61,955,000.00 - $9.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.61
  • P/E Growth: 0.00
  • Market Cap: $891.53M
  • Outstanding Shares: 61,955,000
  • Beta: 0.67
Profitability:
  • Return on Equity: -52.37%
  • Return on Assets: -44.14%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 8.80%
  • Quick Ratio: 8.80%
Additional Links:
Companies Related to Insmed Incorporated:

Analyst Ratings

Consensus Ratings for Insmed Incorporated (NASDAQ:INSM) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $20.75 (44.20% upside)

Analysts' Ratings History for Insmed Incorporated (NASDAQ:INSM)
Show:
DateFirmActionRatingPrice TargetDetails
11/4/2016HC WainwrightReiterated RatingBuyView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00View Rating Details
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details
3/16/2016Citigroup Inc.Lower Price TargetNeutral$21.00 -> $13.00View Rating Details
3/15/2016Stifel NicolausInitiated CoverageBuy$23.00View Rating Details
2/26/2016Leerink SwannLower Price TargetOutperform$29.00 -> $23.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Insmed Incorporated (NASDAQ:INSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
2/23/2017Q316($0.89)($1.10)ViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)ViewN/AView Earnings Details
5/5/2016Q1($0.52)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.56)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.46)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.46)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.41)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insmed Incorporated (NASDAQ:INSM)
Current Year EPS Consensus Estimate: $-2.28 EPS
Next Year EPS Consensus Estimate: $-1.89 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.62)($0.62)($0.62)
Q1 20171($0.58)($0.58)($0.58)
Q2 20171($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insmed Incorporated (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Insmed Incorporated (NASDAQ:INSM)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 92.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.00View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.14View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.00View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.30View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Insmed Incorporated (NASDAQ:INSM)
DateHeadline
News IconInsmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update - P&T Community (NASDAQ:INSM)
www.ptcommunity.com - February 23 at 10:57 PM
finance.yahoo.com logoEdited Transcript of INSM earnings conference call or presentation 23-Feb-17 1:30pm GMT (NASDAQ:INSM)
finance.yahoo.com - February 23 at 10:57 PM
4-traders.com logoInsmed Incorporated : reports 4Q loss (NASDAQ:INSM)
www.4-traders.com - February 23 at 5:55 PM
biz.yahoo.com logoQ4 2016 Insmed Inc Earnings Release - Before Market Open (NASDAQ:INSM)
us.rd.yahoo.com - February 23 at 5:55 PM
us.rd.yahoo.com logoInsmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update (NASDAQ:INSM)
us.rd.yahoo.com - February 23 at 5:55 PM
biz.yahoo.com logoINSMED INC Files SEC form 10-K, Annual Report (NASDAQ:INSM)
us.rd.yahoo.com - February 23 at 5:55 PM
biz.yahoo.com logoINSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:INSM)
us.rd.yahoo.com - February 23 at 5:55 PM
sg.finance.yahoo.com logoInsmed reports 4Q loss (NASDAQ:INSM)
sg.finance.yahoo.com - February 23 at 5:55 PM
News IconLung Infections Industry 2017 Market Analysis Survey Research Growth and Forecast Report 2025 (NASDAQ:INSM)
www.medgadget.com - February 17 at 4:16 PM
finance.yahoo.com logoInsmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017 (NASDAQ:INSM)
finance.yahoo.com - February 16 at 8:09 AM
News IconInsmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New US Patent - P&T Community (NASDAQ:INSM)
www.ptcommunity.com - February 15 at 5:22 AM
finance.yahoo.com logoInsmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent (NASDAQ:INSM)
finance.yahoo.com - February 14 at 7:19 PM
finance.yahoo.com logo8:07 am Insmed announces that the USPTO issued U.S. Patent Number 9,566,234 for ARIKAYCE, the Co's liposomal amikacin for inhalation (NASDAQ:INSM)
finance.yahoo.com - February 14 at 7:19 PM
openpr.com logoAnalysis of Global Growth Factors Market by 2021 (NASDAQ:INSM)
www.openpr.com - February 3 at 6:32 PM
4-traders.com logoSheKnows Media Announces Executive Advisory Board for #BlogHer17, Taking Place June 22-24 in Orlando, Florida (NASDAQ:INSM)
www.4-traders.com - February 2 at 6:36 PM
News IconCould Insmed Incorporated (INSM) Change Direction After Touching 52-Week High? (NASDAQ:INSM)
randolphguide.com - February 2 at 6:36 PM
News IconInsmed Inc INSM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:INSM)
www.bioportfolio.com - January 29 at 11:11 PM
News IconEarnings in Full Force, Analysts Take Aim at Insmed, Inc. (NASDAQ:INSM) - Wall Street Beacon (NASDAQ:INSM)
wsbeacon.com - January 26 at 7:36 PM
openpr.com logoMajor Advancements In The Pseudomonas Aeruginosa Infections Treatment Market Technologies; Global Industry Analysis 2024 (NASDAQ:INSM)
www.openpr.com - January 25 at 7:23 PM
thestreet.com logoFirst Week Of August 18th Options Trading For Insmed (INSM) (NASDAQ:INSM)
www.thestreet.com - January 25 at 7:23 PM
News IconSell-side is Weighing in on Insmed, Inc. (NASDAQ:INSM) Earnings - Aiken Advocate (NASDAQ:INSM)
aikenadvocate.com - January 24 at 11:47 PM
News IconAxial Biotherapeutics Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development (NASDAQ:INSM)
www.enhancedonlinenews.com - January 19 at 7:41 PM
News IconSeton Hall Law School appoints new assistant dean (NASDAQ:INSM)
essexnewsdaily.com - January 16 at 5:54 PM
sbwire.com logoGrowth Factors Market Is Considered as One of the Rapidly Growing Dynamic Markets by 2021 (NASDAQ:INSM)
www.sbwire.com - January 16 at 5:54 PM
investornewswire.com logoInsmed, Inc. (NASDAQ:INSM) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS:378}} - Investor Newswire (NASDAQ:INSM)
www.investornewswire.com - January 13 at 4:26 AM
investornewswire.com logoInsmed, Inc. (NASDAQ:INSM) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:INSM)
www.investornewswire.com - January 13 at 4:26 AM
News IconInsmed, Inc. (INSM) Shares Slip, Investors Watching Closely, Here is Why - BNB Daily (blog) (NASDAQ:INSM)
www.baseball-news-blog.com - January 13 at 4:26 AM
News IconWill The Needle Move For Insmed, Inc. (NASDAQ:INSM) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:INSM)
wsbeacon.com - January 13 at 4:26 AM
seekingalpha.com logoInsmed (INSM) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:INSM)
seekingalpha.com - January 12 at 6:25 PM
News IconGlobal Growth Factors Market Snapshot by 2021 – Persistence Market Research (NASDAQ:INSM)
satprnews.com - January 12 at 4:34 AM
News IconPseudomonas Aeruginosa Infections Treatment Market- New Market Research Report Announced; Global Industry Analysis 2016 – 2024 (NASDAQ:INSM)
www.medgadget.com - January 6 at 6:35 PM
News IconNontuberculous Mycobacteria Research (NASDAQ:INSM)
www.news-medical.net - January 6 at 12:19 AM
News IconEndometriosis Market and Treatment Overview - Global Strategic Business Report (NASDAQ:INSM)
www.econotimes.com - January 4 at 6:50 PM
News IconRetinopathy of Prematurity Market Report Overview, Development and Comparative Analysis 2016 (NASDAQ:INSM)
empowerednews.net - January 4 at 6:50 PM
finance.yahoo.com logoInsmed to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:INSM)
finance.yahoo.com - January 4 at 6:50 PM
openpr.com logoGrowth Factors Market : Global Market Snapshot by 2021 – Persistence Market Research (NASDAQ:INSM)
www.openpr.com - December 30 at 4:08 AM
streetinsider.com logoForm 4 INSMED Inc For: Dec 14 Filed by: Pellizzari Christine A - StreetInsider.com (NASDAQ:INSM)
www.streetinsider.com - December 16 at 6:32 PM
streetinsider.com logoForm 4 INSMED Inc For: Dec 13 Filed by: POTTER MYRTLE S - StreetInsider.com (NASDAQ:INSM)
www.streetinsider.com - December 16 at 4:39 AM
News IconAlexion’s Board of Directors Announces New Leadership Appointments (NASDAQ:INSM)
www.enhancedonlinenews.com - December 12 at 10:51 AM
News IconAlexion CEO and CFO Abruptly Steps Down, Former AstraZeneca PLC CEO Named New Leader (NASDAQ:INSM)
www.biospace.com - December 12 at 10:51 AM
News IconHedge Funds Sour Slightly On Insmed Incorporated (INSM), But Remain Overweight (NASDAQ:INSM)
feedproxy.google.com - December 5 at 12:34 PM
News IconInsmed, Inc. (NASDAQ:INSM) Valuation According To Analysts - UK ... - UK Market News (NASDAQ:INSM)
www.ukmarketnews.co.uk - November 30 at 9:38 AM
News IconInsmed, Inc. (NASDAQ:INSM) Under Analyst Spotlight - UK Market News (NASDAQ:INSM)
www.ukmarketnews.co.uk - November 30 at 9:38 AM
capitalcube.com logoInsmed, Inc. :INSM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:INSM)
www.capitalcube.com - November 29 at 4:30 PM
News IconInsmed Incorporated INSM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:INSM)
www.bioportfolio.com - November 22 at 5:41 PM
News IconStock Update on Earnings & Estimates for Insmed, Inc. (NASDAQ:INSM) - CSZ News (NASDAQ:INSM)
cincysportszone.com - November 22 at 9:38 AM
4-traders.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Insmed, Inc. INSM on Behalf of Shareholders (NASDAQ:INSM)
www.4-traders.com - November 18 at 5:12 PM
News IconBioNJs Second Annual Inspiring Women in STEM Conference (NASDAQ:INSM)
www.cbs58.com - November 17 at 5:14 PM
News IconInsmed Incorporated INSM Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:INSM)
www.bioportfolio.com - November 16 at 5:55 PM
News IconBroker Review: Insmed, Inc. (NASDAQ:INSM) - UK Market News (NASDAQ:INSM)
www.ukmarketnews.co.uk - November 15 at 9:10 AM

Social

What is Insmed Incorporated's stock symbol?

Insmed Incorporated trades on the NASDAQ under the ticker symbol "INSM."

Where is Insmed Incorporated's stock going? Where will Insmed Incorporated's stock price be in 2017?

6 analysts have issued twelve-month price objectives for Insmed Incorporated's shares. Their predictions range from $13.00 to $24.00. On average, they anticipate Insmed Incorporated's stock price to reach $20.75 in the next year.

When will Insmed Incorporated announce their earnings?

Insmed Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

Who owns Insmed Incorporated stock?

Insmed Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Palo Alto Investors LLC (8.80%), Patrick Lee, MD (8.80%), Orbimed Advisors LLC (8.57%), Janus Capital Management LLC (4.61%) and State Street Corp (2.31%). Company insiders that own Insmed Incorporated stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden, Jr, Mark Quigley, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis.

Who sold Insmed Incorporated stock? Who is selling Insmed Incorporated stock?

Insmed Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Janus Capital Management LLC, Frontier Wealth Management LLC and Tudor Investment Corp Et Al. Company insiders that have sold Insmed Incorporated stock in the last year include Andrew T Drechsler, Myrtle S Potter and Orlov S Nicole Schaeffer.

Who bought Insmed Incorporated stock? Who is buying Insmed Incorporated stock?

Insmed Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Paulson & CO. Inc., Alyeska Investment Group L.P., Orbimed Advisors LLC, Denver Investment Advisors LLC, Russell Investments Group Ltd., State Street Corp and Trexquant Investment LP. Company insiders that have bought Insmed Incorporated stock in the last two years include Christine A Pellizzari and William Lewis.

How do I buy Insmed Incorporated stock?

Shares of Insmed Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Insmed Incorporated stock cost?

One share of Insmed Incorporated stock can currently be purchased for approximately $14.39.

Insmed Incorporated (NASDAQ:INSM) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Insmed Incorporated (NASDAQ:INSM)

Earnings History Chart

Earnings by Quarter for Insmed Incorporated (NASDAQ:INSM)

Dividend History Chart

Dividend Payments by Quarter for Insmed Incorporated (NASDAQ:INSM)

Last Updated on 2/26/2017 by MarketBeat.com Staff